Relapse · adults and children with enteric fever
It is very uncertain whether ceftriaxone changes relapse compared with fluoroquinolones (very low certainty).
1 finding from 1 review
Time to defervescence · adults and children with enteric fever
It is very uncertain whether ceftriaxone changes time to defervescence compared with fluoroquinolones (very low certainty).
1 finding from 1 review
Length of hospital stay · adults and children with enteric fever
1 finding from 1 review
Microbiological failure · adults and children with enteric fever
Cefixime showed no clear difference in microbiological failure compared with fluoroquinolones (low certainty).
1 finding from 1 review
Convalescent faecal carriage · adults and children with enteric fever
It is very uncertain whether ceftriaxone changes convalescent faecal carriage compared with fluoroquinolones (very low certainty).
1 finding from 1 review
Serious adverse events · adults and children with enteric fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · adults and children with enteric fever
Cefixime may leads to higher relapse compared with fluoroquinolones (low certainty).
1 finding from 1 review
Time to defervescence · adults and children with enteric fever
Cefixime may leads to higher time to defervescence compared with fluoroquinolones (low certainty).
1 finding from 1 review
Length of hospital stay · adults and children with enteric fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Convalescent faecal carriage · adults and children with enteric fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults and children with enteric fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at last · people with liver metastases
It is very uncertain whether summary of Findings Table ‐ Electrocoagulation alone changes all‐cause mortality at last compared with control (vehicle solution of allopurinol by mouth) (very low certainty).
1 finding from 1 review
Post‐operative deaths · people with liver metastases
It is very uncertain whether summary of Findings Table ‐ Electrocoagulation alone changes post‐operative deaths compared with control (vehicle solution of allopurinol by mouth) (very low certainty).
1 finding from 1 review
Other adverse events and complications · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
Failure to clear liver metastases or recurrence of liver metastases · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
Tumour response · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
sUA reduction · participants with chronic gout and sUA level > 0.36mmol/L
1 finding from 1 review
Joint pain reduction ‐ not reported · participants with chronic gout and sUA level > 0.36mmol/L
The review found no eligible studies for this question.
1 finding from 1 review
Participant global assessment · participants with chronic gout and sUA level > 0.36mmol/L
The review found no eligible studies for this question.
1 finding from 1 review
Total adverse events · participants with chronic gout and sUA level > 0.36mmol/L
1 finding from 1 review